Understanding Carotid Atherosclerosis and Endothelial Complexity

Carotid atherosclerosis remains a significant challenge in modern cardiology, particularly regarding the mechanisms that lead to plaque rupture and subsequent ischemic stroke. Recent research has shed light on the specialized role of PGF+ endothelial cells in mediating vascular inflammation and structural destabilization within the arterial wall. By utilizing advanced single-cell technologies, scientists are now able to dissect the intricate heterogeneity of the vascular endothelium at a resolution previously deemed impossible. This progress is particularly relevant for clinical practice in India, where the burden of cardiovascular and cerebrovascular diseases continues to rise among diverse populations. Understanding how specific endothelial subsets contribute to the transition from stable to unstable plaques provides a critical foundation for developing more targeted therapeutic interventions. Furthermore, identifying these cells allows clinicians to better predict which patients are at a higher risk of symptomatic events. As a result, the study of endothelial diversity has shifted from a general observation of vascular dysfunction to a precise molecular characterization of cell states. Consequently, these findings offer a new perspective on the biological triggers that convert a dormant atherosclerotic lesion into a life-threatening clinical event.

The Pro-inflammatory Role of PGF+ Endothelial Cells

Placental growth factor, commonly known as PGF, is a member of the vascular endothelial growth factor family that has long been associated with angiogenesis and inflammatory responses. In the context of atherosclerosis, the presence of PGF+ endothelial cells appears to indicate a shift toward a highly active and damaging vascular phenotype. Researchers have observed that these specific cells are not uniformly distributed but are instead concentrated within unstable segments of the carotid artery. Moreover, these subsets exhibit a significant upregulation of multiple pro-inflammatory cytokines, which recruits further immune cells to the plaque site. This recruitment process creates a self-sustaining cycle of inflammation that weakens the fibrous cap of the plaque. Additionally, the study indicates that these endothelial cells are actively involved in promoting vascular permeability, which further compromises the integrity of the vessel wall. Therefore, PGF acts as more than just a marker; it functions as a functional driver of the pathological changes seen in advanced lesions. By focusing on these subsets, the medical community can better understand the early warning signs of plaque instability. In addition, this molecular focus helps in distinguishing between different types of vascular aging and true disease progression.

Integrating scRNA-seq and Bulk RNA-seq Analysis

To achieve these insights, the study utilized a sophisticated integrated analysis of single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data. This multi-layered approach allowed investigators to characterize endothelial cell heterogeneity with unprecedented precision. Specifically, the analysis identified three distinct endothelial cell subsets, labeled as subsets 9, 10, and 11, which were significantly enriched in unstable plaques. Unlike standard endothelial cells, these clusters showed a unique transcriptomic profile that favored inflammatory pathways over normal homeostatic functions. Furthermore, gene set variation analysis (GSVA) confirmed that these subsets were not merely coincidental but were fundamentally linked to the disease process. Transitioning from broad tissue analysis to single-cell resolution reveals that the vascular wall is a mosaic of different cellular behaviors. Consequently, the research highlights that a "one-size-fits-all" approach to treating endothelial dysfunction may be insufficient. Instead, targeting the specific pathways active in these problematic clusters could provide more effective outcomes for patients. Moreover, the integration of different sequencing methods ensures that the findings are robust and reproducible across different patient cohorts. This rigorous methodology strengthens the conclusion that specific endothelial subsets are key players in the progression of carotid artery disease.

Signalling Mechanisms: PI3K-Akt and Plaque Instability

One of the most significant findings of the research was the identification of the PI3K - Akt signaling pathway as a primary mediator of endothelial inflammation. Pathway analysis revealed that the problematic PGF+ endothelial cells subsets were heavily associated with the activation of this specific signaling cascade. This discovery is vital because the PI3K-Akt pathway is known to regulate various cellular processes, including survival, proliferation, and the release of inflammatory mediators. In the environment of an atherosclerotic plaque, overactivation of this pathway in endothelial cells appears to exacerbate the recruitment of macrophages and other leukocytes. Consequently, this leads to an increase in the production of matrix metalloproteinases, which are enzymes that degrade the structural proteins of the plaque. Therefore, the PI3K-Akt axis represents a potential therapeutic target for stabilizing carotid lesions before they rupture. Furthermore, other inflammation-related pathways were also found to be upregulated, suggesting a complex network of signaling that drives the unstable phenotype. By understanding these molecular interactions, clinicians can explore the use of existing or novel inhibitors to dampen this specific inflammatory response. As a result, the management of atherosclerosis could move toward a more personalized, molecularly-driven strategy in the future.

Experimental Validation in ApoE-Deficient Models

To ensure the clinical relevance of the transcriptomic findings, the researchers conducted validation experiments in an apolipoprotein E-deficient (ApoE-/-) mouse model. This model is widely recognized as a gold standard for studying human-like atherosclerotic lesions in a controlled environment. The results in the animal model mirrored the human data, showing a marked increase in PGF expression within diseased vascular segments. Specifically, the proportion of PGF-positive endothelial cells was significantly higher in mice with advanced atherosclerotic lesions compared to controls. This validation provides strong evidence that the presence of these cells is a consistent feature of plaque development across species. Moreover, the increased expression of PGF in these lesions was directly correlated with markers of plaque instability, such as reduced collagen content and increased necrotic core size. Additionally, the experimental data confirmed that the activation of the PI3K-Akt pathway was a prominent feature in the mouse endothelial cells as well. This cross-species consistency suggests that the biological mechanisms identified are fundamental to the pathology of atherosclerosis. Consequently, the use of ApoE-/- models continues to be an invaluable tool for testing new therapeutic agents that target specific endothelial subsets. Therefore, these experimental findings reinforce the potential of PGF as a therapeutic and diagnostic focus.

Future Clinical Directions for Atherosclerosis Management

The identification of these specific pro-inflammatory endothelial subsets opens several new avenues for the management of atherosclerosis in India. Currently, clinical practice heavily relies on imaging techniques like ultrasound or CT angiography to assess the degree of carotid stenosis. However, these methods often fail to capture the underlying biological activity that determines whether a plaque will actually rupture. By incorporating molecular markers such as PGF into risk assessment protocols, physicians could potentially achieve a higher degree of diagnostic accuracy. Furthermore, the development of targeted therapies that specifically inhibit the PI3K-Akt pathway or PGF activity within the endothelium could provide a new layer of protection against stroke. In addition to traditional statin therapy, these molecularly targeted approaches could help stabilize plaques in high-risk individuals. Moreover, the study emphasizes the importance of early intervention, as the pro-inflammatory subsets appear to be active long before a clinical event occurs. Therefore, moving toward a proactive, biology-first approach could significantly reduce the incidence of ischemic stroke in the Indian population. As research continues to evolve, the integration of single-cell transcriptomics into clinical diagnostics may eventually become a reality. Consequently, this study provides a vital stepping stone toward a more precise and effective era of cardiovascular medicine.

Frequently Asked Questions

What is the significance of PGF+ endothelial cells in carotid plaques?

PGF+ endothelial cells are a specialized subset of vascular cells that become highly active in unstable atherosclerotic plaques. Unlike normal endothelial cells, these subsets release pro-inflammatory cytokines and activate pathways like PI3K-Akt. Their presence is directly linked to the destabilization of the carotid plaque, making them a critical marker for identifying patients at high risk for ischemic stroke and other cardiovascular complications. Understanding these cells helps in developing targeted vascular therapies.

How does scRNA-seq improve our understanding of atherosclerosis compared to traditional methods?

Traditional bulk RNA-seq provides an average gene expression profile for an entire tissue sample, often masking the unique activities of rare cell types. In contrast, scRNA-seq allows researchers to examine the transcriptomic profile of each individual cell. This precision enables the identification of specific, high-risk endothelial subsets, such as those expressing PGF, which would otherwise be hidden. This granular view is essential for uncovering the diverse cellular mechanisms that drive plaque progression.

What are the potential therapeutic targets suggested by this study?

The study highlights the PI3K-Akt signaling pathway and the Placental Growth Factor (PGF) protein as primary therapeutic targets. Since these are upregulated in the endothelial subsets associated with plaque instability, inhibiting them could potentially reduce vascular inflammation and strengthen the plaque structure. Such targeted interventions could complement existing treatments like statins and antiplatelet agents, providing a more comprehensive approach to preventing plaque rupture and subsequent clinical events like strokes or heart attacks.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Xiang Y et al. Identification of PGF+ endothelial cells associated with plaque instability in carotid atherosclerosis by scRNA-seq and RNA-seq analysis. Cell Cycle. 2026 Dec undefined. doi: 10.1080/15384101.2026.2688663. PMID: 42365589.